
Sean Agbor-Enoh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6883972/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cell-Free DNA to Detect Heart Allograft Acute Rejection. Circulation, 2021, 143, 1184-1197.	1.6	129
2	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight, 2021, 6, .	2.3	86
3	Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine, 2019, 40, 541-553.	2.7	83
4	The SIRPα–CD47 immune checkpoint in NK cells. Journal of Experimental Medicine, 2021, 218, .	4.2	82
5	De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nature Biotechnology, 2019, 37, 1137-1144.	9.4	74
6	Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. Journal of Heart and Lung Transplantation, 2018, 37, 925-932.	0.3	69
7	Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1004-1012.	0.3	45
8	Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. Journal of Heart and Lung Transplantation, 2021, 40, 822-830.	0.3	34
9	Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics. Journal of Heart and Lung Transplantation, 2021, 40, 405-413.	0.3	28
10	Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). Journal of Heart and Lung Transplantation, 2021, 40, 488-493.	0.3	26
11	Circulating cell-free DNA as a biomarker of tissue injury: Assessment in a cardiac xenotransplantation model. Journal of Heart and Lung Transplantation, 2018, 37, 967-975.	0.3	25
12	The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. Biomedicines, 2021, 9, 1090.	1.4	22
13	Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. Journal of Heart and Lung Transplantation, 2022, 41, 458-466.	0.3	20
14	Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury. Journal of Heart and Lung Transplantation, 2021, 40, 1454-1462.	0.3	13
15	Comparison of donor-derived cell-free DNA between single versus double lung transplant recipients. American Journal of Transplantation, 2022, 22, 2451-2457.	2.6	11
16	Higher levels of allograft injury in black patients early after heart transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 855-858.	0.3	11
17	Circulating microRNAs in cellular and antibody-mediated heart transplant rejection. Journal of Heart and Lung Transplantation, 2022, 41, 1401-1413.	0.3	11
18	Cell-free DNA in lung transplantation: research tool or clinical workhorse?. Current Opinion in Organ Transplantation, 2022, 27, 177-183.	0.8	8

Sean Agbor-Enoh

#	Article	IF	CITATIONS
19	2018 ATS BEAR Cage Winning Proposal: Cell-Free DNA to Improve Lung Transplant Outcomes. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1058-1060.	2.5	7
20	Donor-Derived Cell-Free DNA for Acute Rejection Monitoring in Heart and Lung Transplantation. Current Transplantation Reports, 2021, 8, 351-358.	0.9	7
21	Transcriptomics in transplantation: More than just biomarkers of allograft rejection. American Journal of Transplantation, 2021, 21, 2000-2001.	2.6	6
22	OUP accepted manuscript. Clinical Chemistry, 2021, 67, 1443-1449.	1.5	5
23	The effect of the cystic fibrosis care center on outcomes after lung transplantation for cystic fibrosis. Journal of Heart and Lung Transplantation, 2022, 41, 300-307.	0.3	5
24	Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients. journal of applied laboratory medicine, The, 2022, , .	0.6	4
25	The ISHLT Chronic Lung Allograft Dysfunction Consensus Criteria is Applicable to Pulmonary Chronic Graft-versus-Host Disease. Blood Advances, 2022, , .	2.5	3
26	Lie Down and Breathe. Annals of the American Thoracic Society, 2014, 11, 1155-1158.	1.5	1
27	Noninvasive biomarkers in heart transplant: 2020–2021 year in review. Current Opinion in Organ Transplantation, 2022, 27, 7-14.	0.8	1
28	Environment, Epigenetics, and Differential Responses to Beryllium Exposure: Are We There Yet?. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 11-12.	1.4	0
29	Response by Shah et al to Letter Regarding Article, "Cell-Free DNA to Detect Heart Allograft Acute Rejection― Circulation, 2021, 144, e198-e199.	1.6	Ο